Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.
Syntara Limited (PMXSF) conducted an investor webinar and Q&A session on April 29 at 9:00 PM EDT, following key announcements. CEO Gary Phillips, MD and Director, presented updates on the lead asset amsulostat, FDA interactions, capital raising, and the latest quarterly cash flow report filed with the ASX as Appendix 4C. Matthew Wright hosted the call, introducing Phillips to address investor interests directly. Gary Phillips emphasized the positive FDA review of amsulostat, building on Phase II data reported last year. The agency has agreed on a way forward for the Phase IIb trial in myelofibrosis, which Phillips described as significant for shareholders and the company's next steps. The capital raise features an $8 million placement, bringing pro forma cash to $16.9 million, excluding any proceeds from the Share Purchase Plan. Phillips noted this positions Syntara through the third quarter. Investors joined via operator instructions for questions at the end.
